{
    "nctId": "NCT01769625",
    "briefTitle": "Changes in Biomarkers Using Prostaglandin Inhibitors",
    "officialTitle": "Prostaglandin Inhibition to Prevent Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Biomarker Change Linked to Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 31,
    "primaryOutcomeMeasure": "PG synthesis and metabolism, through the measurement of PGE2, COX-2 and 15-PGDH in the breast",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Woman \\>18 years old\n* Healthy women who are at normal risk for developing breast cancer\n* ECOG Performance Status score 0-1\n* Premenopausal women must not be pregnant\n\nExclusion Criteria:\n\n* History of bilateral mastectomy, or bilateral breast irradiation\n* Significant medical or psychiatric problems making the participant a poor candiate\n* Evidence of excess use of narcotics or drug dependency\n* Have been pregnant and lactating in the past 2 years\n* Significant history of peptic ulcer disease or upper gastrointestinal bleeding\n* History of severe congestive heart failure that requires hospitalization or intervention\n* History of asthma requiring medication for treatment\n* Allergy to sulfonamides or NSAID medications\n* History of myocardial infarction or stroke\n* Currently on Coumadin\n* Currently on Tamoxifen (nolvadex),Evista (raloxifene), Femara (letrozole), Arimidex (anastrozole), or Aromasin (exemestane)\n* Undergone prior subaeolar breast surgery",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}